AMA CPT® Assistant - 2007 Issue 7 (July)
Medicine: Vaccines, Toxoids (July 2007)
July 2007 page 13b Coding Communication: Medicine: Vaccines, Toxoids Question For CPT 2006 , code 90649 , Human papilloma virus (HPV) vaccine, types 6, 11, 16, 18 (quadrivalent), 3 dose schedule, for intramuscular use , was designated with an Food and Drug Administration (FDA) approval pending symbol. Upon review of the 2007 CPT codebook, I realize that the designation is no longer applied to code 90649 . The removal of the FDA approval pending symbol leads one to believe that code 90649 has now received FDA approval. Is this correct? If so, is it appropriate to report code 90649 for either males or...
Subscribe or sign in to view the full article.
Article Overview
This article is a short CPT Assistant coding communication for the Medicine: Vaccines, Toxoids category. It explains a reader question about a vaccine-related CPT code, the removal of an FDA approval pending designation, and how the code relates to patient sex in the context of FDA approval. It is relevant to coders, billing staff, and compliance teams working with vaccine reporting and CPT codebook changes.
Why This Topic Matters
It helps readers interpret a coding update tied to vaccine reporting and understand how a codebook symbol change relates to regulatory status and reporting. This is important for accurate CPT usage and for keeping coding practices aligned with current guidance.
What You Will Learn
- How a CPT vaccine-related code can be affected by a change in FDA approval status.
- How to interpret a codebook symbol change in a vaccine coding context.
- How the article frames the relationship between regulatory approval and patient reporting context.
- What type of coding question prompted the communication.
Who Should Read This
- Medical coders
- Billing specialists
- Compliance professionals
- Physician office staff
- Revenue cycle teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com
